desk
Share
Alembic Pharma informed in an exchange filing on Friday that the US Food and Drug Administration (US FDA) has completed the inspection of the company's API-III facility located at Karakhadi. The company said that the US FDA has not issued any Form 483 observation. The US FDA inspected the API-III facility from March 17-21, 2025.
The company said in an exchange filing that the company has successfully completed the United States Food and Drug Administration (USFDA) inspection for its API-III facility located at Karakhadi. It was a scheduled GMP inspection and was successfully completed without any Form 483 observation. The inspection was conducted from March 17, 2025 to March 21, 2025.'' Stock performance The company's stock closed 8.43 per cent higher at Rs 905.05 on Friday.
--Advertisement--
